Hepatitis B Vaccine Recombinant

Hepatitis B Vaccine Recombinant Brand Names

Engerix-B | H-B-Vax | HEPLISAV-B | RDNA H-B Vax II | Recombivax HB

What is Hepatitis B Vaccine Recombinant

Vaccines against hepatitis B surface antigen (HBsAg) are produced by yeast cells utilizing recombinant technology designed for intramuscular or subcutaneous (Engerix-B and Recombivax HB only) administration.

The recombinant hepatitis B vaccines contain no human blood products.

Engerix-B and Heplisav-B reportedly contain not more than 5% yeast proteins while Recombivax HB contains not more than 1%.

Engerix-B and Recombivax HB are indicated for hepatitis B prophylaxis in all ages and can be used in conjunction with hepatitis B immune globulin (HBIG) for postexposure prophylaxis. Heplisav-B is indicated for hepatitis B prophylaxis in adults 18 years of age and older.

The first dose of the hepatitis B vaccine (Engerix-B or Recombivax HB) should be given to all neonates within 24 hours of birth.

For infants born to hepatitis B surface antigen (HBsAg) positive mothers, the hepatitis B vaccine and hepatitis B immune globulin (HBIG) should be administered within 12 hours of birth.

If the mother’s HBsAg status is unknown, the hepatitis B vaccine should be administered to all neonates within 12 hours of birth.

Additionally, HBIG should be administered within 12 hours to all neonates weighing less than 2 kg and within 7 days if the mother is determined to be HBsAg positive in neonates weighing more than 2 kg

Indications

  • hepatitis B prophylaxis

Side Effects

  1. abdominal pain
  2. agitation
  3. alopecia
  4. anaphylactic shock
  5. anaphylactoid reactions
  6. angioedema
  7. anorexia
  8. arthralgia
  9. back pain
  10. chills
  11. constipation
  12. diarrhea
  13. dizziness
  14. dyspepsia
  15. dyspnea
  16. ecchymosis
  17. encephalopathy
  18. erythema
  19. erythema multiforme
  20. erythema nodosum
  21. fatigue
  22. fever
  23. flushing
  24. Guillain-Barre syndrome
  25. headache
  26. hypoesthesia
  27. hypotension
  28. injection site reaction
  29. insomnia
  30. irritability
  31. lichen planus-like eruption
  32. lymphadenopathy
  33. malaise
  34. migraine
  35. myalgia
  36. myelitis
  37. myocardial infarction
  38. nausea
  39. neuritis
  40. optic neuritis
  41. paresthesias
  42. peripheral neuropathy
  43. petechiae
  44. pruritus
  45. purpura
  46. rash
  47. seizures
  48. serum sickness
  49. Stevens-Johnson syndrome
  50. syncope
  51. thrombocytopenia
  52. tinnitus
  53. urticaria
  54. vasculitis
  55. vertigo
  56. vomiting
  57. weakness

Monitoring Parameters

  • hepatitis B serology

Contraindications

  • anticoagulant therapy
  • breast-feeding
  • cardiac disease
  • chemotherapy
  • coagulopathy
  • dialysis
  • fever
  • hemophilia
  • human immunodeficiency virus (HIV) infection
  • immunosuppression
  • infection
  • intravenous administration
  • laboratory test interference
  • latex hypersensitivity
  • neonates
  • pregnancy
  • premature neonates
  • renal disease
  • renal failure
  • subcutaneous administration
  • thrombocytopenia
  • vitamin K deficiency
  • yeast hypersensitivity

Interactions

  • Hepatitis B Immune Globulin, HBIG
  • Ocrelizumab
  • Siponimod
You cannot copy content of this page